These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 26324366)
41. Multitiered Questions Regarding Multigene Testing for Cancer Susceptibility. Newman LA JAMA Surg; 2018 Nov; 153(11):983-984. PubMed ID: 30264135 [No Abstract] [Full Text] [Related]
42. European Organisation for Research and Treatment of Cancer's point of view. Meunier F; Lacombe D Lancet; 2003 Aug; 362(9384):663. PubMed ID: 12944069 [No Abstract] [Full Text] [Related]
43. Suit signals cancer services fight. Lutz S Mod Healthc; 1996 Apr; 26(16):24. PubMed ID: 10156894 [No Abstract] [Full Text] [Related]
44. Preimplantation diagnosis for genetic susceptibility. Gibbons WE N Engl J Med; 2006 Nov; 355(19):2048. PubMed ID: 17093261 [No Abstract] [Full Text] [Related]
45. Genetic testing of children for cancer susceptibility. Uzych L J Pediatr Oncol Nurs; 1996 Oct; 13(4):194-5. PubMed ID: 8908904 [No Abstract] [Full Text] [Related]
46. Genetic testing: technology that is changing the adoption process. Schlee JA N Y Law Sch J Hum Rights; 2001; 18(1):133-83. PubMed ID: 12962109 [No Abstract] [Full Text] [Related]
47. The potential for misusing "genetic predisposition" in Canadian courts and tribunals. Mykitiuk R; Pioro M; Finkler L; Nisker J CMAJ; 2011 Oct; 183(14):1601-4. PubMed ID: 21609997 [No Abstract] [Full Text] [Related]
48. "It Is What It Is". Oosterwijk JC J Clin Oncol; 2016 Apr; 34(11):1278-80. PubMed ID: 26884556 [No Abstract] [Full Text] [Related]
50. Reflections on the European Conference "Molecular Screening of Individuals at High Risk for Developing Cancer: Medical, Ethical, Legal, and Social Issues". Kataki A; Konstadoulakis MM Genet Test; 2000; 4(1):79-84. PubMed ID: 10794367 [TBL] [Abstract][Full Text] [Related]
51. [Diffusion of genetic testing in oncology: what criteria for regulation?]. Eisinger F; Moatti JP Med Sci (Paris); 2007 Mar; 23(3):327-32. PubMed ID: 17349298 [TBL] [Abstract][Full Text] [Related]
52. Predicting the performance of a genetic testing service for cancer susceptibility. Bajdik CD; Sung S; Spinelli JJ; Huntsman D; Gallinger S; Horsman D; Gallagher RP Genet Test; 2007; 11(4):381-6. PubMed ID: 18294053 [TBL] [Abstract][Full Text] [Related]
53. Multiplex genetic testing for cancer susceptibility: out on the high wire without a net? Domchek SM; Bradbury A; Garber JE; Offit K; Robson ME J Clin Oncol; 2013 Apr; 31(10):1267-70. PubMed ID: 23460708 [No Abstract] [Full Text] [Related]
54. Cancer family history and genetic testing: are malpractice adjudications waiting to happen? Lynch HT Am J Gastroenterol; 2002 Mar; 97(3):518-20. PubMed ID: 11922540 [No Abstract] [Full Text] [Related]
55. The coming era of cancer genetic screening. Grody WW Diagn Mol Pathol; 1994 Sep; 3(3):145-6. PubMed ID: 7981888 [No Abstract] [Full Text] [Related]
56. Multigene Panel Testing in Oncology Practice: How Should We Respond? Kurian AW; Ford JM JAMA Oncol; 2015 Jun; 1(3):277-8. PubMed ID: 26181167 [No Abstract] [Full Text] [Related]
57. Conversion technology and cancer predispositions. Papadopoulos N Methods Mol Biol; 2003; 223():415-23. PubMed ID: 12777743 [No Abstract] [Full Text] [Related]
59. Insurance, genetic testing and familial cancer: recent policy changes in the United Kingdom. Morrison PJ Ulster Med J; 2001 Nov; 70(2):79-88. PubMed ID: 11795771 [No Abstract] [Full Text] [Related]
60. Informed consent for BRCA1 and BRCA2 testing: what clinicians should know about the process and content. Miesfeldt S; Jones SM; Cohn WF J Am Med Womens Assoc (1972); 2000; 55(5):275-9. PubMed ID: 11070646 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]